Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1
Open Access
- 19 July 2010
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 98
Abstract
Background: The novel gene HA117 is a multidrug resistance (MDR) gene expressed by all-trans retinoic acid-resistant HL-60 cells. In the present study, we compared the multidrug resistance of the HA117 with that of the classical multidrug resistance gene 1 (MDR1) in breast cancer cell line 4T1. Methods: Transduction of the breast cancer cell line 4T1 with adenoviral vectors encoding the HA117 gene and the green fluorescence protein gene (GFP) (Ad-GFP-HA117), the MDR1 and GFP (Ad-GFP-MDR1) or GFP (Ad-GFP) was respectively carried out. The transduction efficiency and the multiplicity of infection (MOI) were detected by fluorescence microscope and flow cytometry. The transcription of HA117 gene and MDR1 gene were detected by reverse transcription polymerase chain reaction (RT-PCR). Western blotting analysis was used to detect the expression of P-glycoprotein (P-gp) but the expression of HA117 could not be analyzed as it is a novel gene and its antibody has not yet been synthesized. The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) efflux assay. The drug sensitivities of 4T1/HA117 and 4T1/MDR1 to chemotherapeutic agents were detected by Methyl-Thiazolyl-Tetrazolium (MTT) assay. Results: The transducted efficiency of Ad-GFP-HA117 and Ad-GFP-MDR1 were 75%-80% when MOI was equal to 50. The transduction of Ad-GFP-HA117 and Ad-GFP-MDR1 could increase the expression of HA117 and MDR1. The drug resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as compared to the control cells. There were no significant differences in drug sensitivity between 4T1/HA117 and 4T1/MDR1 for the P-gp substrates (ADM, VCR and Taxol) (P < 0.05), while the difference between them for P-gp non-substrate (BLM) was statistically significant (P < 0.05). DNR efflux assay confirmed that the multidrug resistance mechanism of HA117 might not be similar to that of MDR1. Conclusions: These results confirm that HA117 is a strong MDR gene in both HL-60 and 4T1 cells. Furthermore, our results indicate that the MDR mechanism of the HA117 gene may not be similar to that of MDR1.Keywords
This publication has 24 references indexed in Scilit:
- RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myelomaBlood, 2009
- HA117 gene increased the multidrug resistance of K562 cells in vitro: an investigation to the function of a novel gene related to drug resistanceJournal of Experimental & Clinical Cancer Research, 2009
- Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS PatientsOncology Research and Treatment, 2008
- MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AMLBlood, 2007
- A protocol for rapid generation of recombinant adenoviruses using the AdEasy systemNature Protocols, 2007
- Multiple molecular mechanisms for multidrug resistance transportersNature, 2007
- Multidrug Resistance in Locally Advanced Breast CancerTumor Biology, 2006
- Retinoic acid resistance in acute promyelocytic leukemiaLeukemia, 2002
- Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-transretinoic acid and histone deacetylase inhibitors in vitro and in vivoBlood, 2002
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1976